Infant Bacterial Therapeutics AB (osto:IBT B) Share Price

Company Profile

Business description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Contact
Katarina Bangata 70
Stockholm116 42
SWE
T: +46 762193738
https://www.ibtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6

Recommended

We think the floundering stock price is not reflective of underlying asset value.

Brian Han | 10 April 2026

Near-term cost growth does not change our long-term view.

Shane Ponraj, CFA | 10 April 2026

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Johannes Faul, CFA | 09 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,155.80	34.00	0.37%
CAC 40	8,259.60	13.81	0.17%
DAX 40	23,803.95	3.04	-0.01%
Dow JONES (US)	47,916.57	269.23	-0.56%
FTSE 100	10,600.53	2.95	-0.03%
HKSE	25,893.54	141.14	0.55%
NASDAQ	22,902.89	80.48	0.35%
Nikkei 225	56,924.11	1,028.79	1.84%
NZX 50 Index	13,181.44	92.37	-0.70%
S&P 500	6,816.89	7.77	-0.11%
S&P/ASX 200	8,960.60	36.20	0.41%
SSE Composite Index	3,986.22	20.05	0.51%